- Home
- ACT vs TMDX Comparison
ACT vs TMDX Comparison
Compare ACT & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACT
- TMDX
- Stock Information
- Founded
- ACT 1981
- TMDX 1998
- Country
- ACT United States
- TMDX United States
- Employees
- ACT N/A
- TMDX N/A
- Industry
- ACT Specialty Insurers
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ACT Finance
- TMDX Health Care
- Exchange
- ACT Nasdaq
- TMDX Nasdaq
- Market Cap
- ACT 5.3B
- TMDX 2.1B
- IPO Year
- ACT 2021
- TMDX 2019
- Fundamental
- Price
- ACT $31.74
- TMDX $62.54
- Analyst Decision
- ACT Buy
- TMDX Buy
- Analyst Count
- ACT 4
- TMDX 11
- Target Price
- ACT $36.50
- TMDX $116.10
- AVG Volume (30 Days)
- ACT 228.4K
- TMDX 2.5M
- Earning Date
- ACT 02-04-2025
- TMDX 02-24-2025
- Dividend Yield
- ACT 2.25%
- TMDX N/A
- EPS Growth
- ACT 6.96
- TMDX N/A
- EPS
- ACT 4.29
- TMDX 0.94
- Revenue
- ACT $1,196,188,000.00
- TMDX $401,090,000.00
- Revenue This Year
- ACT N/A
- TMDX $81.61
- Revenue Next Year
- ACT $4.81
- TMDX $22.52
- P/E Ratio
- ACT $7.40
- TMDX $66.74
- Revenue Growth
- ACT 5.45
- TMDX 109.09
- 52 Week Low
- ACT $26.13
- TMDX $58.27
- 52 Week High
- ACT $37.42
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- ACT 36.24
- TMDX 40.85
- Support Level
- ACT $30.79
- TMDX $58.40
- Resistance Level
- ACT $32.71
- TMDX $82.37
- Average True Range (ATR)
- ACT 0.48
- TMDX 4.34
- MACD
- ACT -0.05
- TMDX 1.04
- Stochastic Oscillator
- ACT 43.88
- TMDX 17.72
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers they will use for the placement of mortgage insurance written on loans they originate. The company is engaged in the business of writing and assuming residential mortgage guaranty insurance.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.